Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Gene Regulatory Networks | 3 | 2020 | 820 | 0.72 | Why? |
| Skin Diseases, Viral | 1 | 2020 | 436 | 0.53 | Why? |
| Obsessive-Compulsive Disorder | 1 | 2021 | 486 | 0.53 | Why? |
| Bronchi | 1 | 2020 | 1048 | 0.51 | Why? |
| Cytomegalovirus | 1 | 2018 | 600 | 0.48 | Why? |
| Respiratory Mucosa | 1 | 2020 | 1522 | 0.44 | Why? |
| HIV Infections | 13 | 2020 | 11620 | 0.44 | Why? |
| Cytomegalovirus Infections | 1 | 2018 | 667 | 0.44 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2010 | 170 | 0.40 | Why? |
| Transcriptome | 2 | 2020 | 3466 | 0.40 | Why? |
| Carcinoma, Hepatocellular | 1 | 2017 | 1222 | 0.34 | Why? |
| Autoimmune Diseases | 1 | 2021 | 1996 | 0.34 | Why? |
| 2',5'-Oligoadenylate Synthetase | 2 | 2018 | 205 | 0.32 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.31 | Why? |
| Hypoglycemia | 1 | 2010 | 406 | 0.30 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.30 | Why? |
| Antiretroviral Therapy, Highly Active | 4 | 2019 | 952 | 0.28 | Why? |
| Skin Diseases | 1 | 2020 | 2509 | 0.26 | Why? |
| Dyneins | 1 | 2020 | 9 | 0.22 | Why? |
| Conjunctival Diseases | 1 | 2020 | 32 | 0.21 | Why? |
| Sarcoma, Kaposi | 2 | 2019 | 97 | 0.20 | Why? |
| Anti-HIV Agents | 5 | 2019 | 2209 | 0.20 | Why? |
| Brucella melitensis | 1 | 2019 | 10 | 0.20 | Why? |
| HLA-C Antigens | 1 | 2021 | 195 | 0.20 | Why? |
| Carcinoembryonic Antigen | 1 | 2020 | 140 | 0.20 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.19 | Why? |
| Venous Thromboembolism | 1 | 2018 | 4273 | 0.19 | Why? |
| GPI-Linked Proteins | 1 | 2020 | 317 | 0.19 | Why? |
| Anti-Infective Agents | 1 | 2010 | 1766 | 0.19 | Why? |
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 264 | 0.18 | Why? |
| Brucellosis | 1 | 2019 | 49 | 0.18 | Why? |
| Lipodystrophy | 1 | 2017 | 18 | 0.18 | Why? |
| Nanotubes, Carbon | 1 | 2018 | 71 | 0.18 | Why? |
| Corneal Diseases | 1 | 2020 | 172 | 0.18 | Why? |
| Contraceptives, Oral, Hormonal | 1 | 2018 | 42 | 0.17 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.17 | Why? |
| Multigene Family | 1 | 2018 | 377 | 0.17 | Why? |
| Hepatitis B Vaccines | 1 | 2019 | 245 | 0.16 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2019 | 309 | 0.16 | Why? |
| Eye | 1 | 2020 | 374 | 0.16 | Why? |
| Blood Glucose | 1 | 2010 | 3642 | 0.16 | Why? |
| Complement C1 Inhibitor Protein | 1 | 2017 | 124 | 0.16 | Why? |
| Q Fever | 1 | 2018 | 130 | 0.15 | Why? |
| Dermatomyositis | 1 | 2018 | 193 | 0.15 | Why? |
| Drugs, Investigational | 1 | 2019 | 198 | 0.15 | Why? |
| Neurocognitive Disorders | 1 | 2017 | 99 | 0.15 | Why? |
| Erythema | 1 | 2020 | 400 | 0.15 | Why? |
| Psoriasis | 2 | 2020 | 1739 | 0.15 | Why? |
| Personnel, Hospital | 2 | 2019 | 2273 | 0.15 | Why? |
| Simian Acquired Immunodeficiency Syndrome | 1 | 2017 | 154 | 0.15 | Why? |
| Dysgeusia | 1 | 2020 | 524 | 0.14 | Why? |
| Taste | 1 | 2020 | 715 | 0.14 | Why? |
| Sicily | 3 | 2019 | 153 | 0.14 | Why? |
| Coronavirus | 2 | 2021 | 18339 | 0.14 | Why? |
| Arthritis, Psoriatic | 1 | 2020 | 625 | 0.14 | Why? |
| Acquired Immunodeficiency Syndrome | 2 | 2019 | 533 | 0.13 | Why? |
| Environmental Microbiology | 1 | 2019 | 575 | 0.13 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.13 | Why? |
| Drug Users | 1 | 2017 | 234 | 0.13 | Why? |
| Hematology | 1 | 2020 | 649 | 0.13 | Why? |
| Central Nervous System | 1 | 2018 | 701 | 0.12 | Why? |
| Coronavirus Infections | 10 | 2021 | 253789 | 0.12 | Why? |
| Chilblains | 2 | 2020 | 1156 | 0.12 | Why? |
| Diagnosis, Differential | 4 | 2021 | 7220 | 0.12 | Why? |
| Up-Regulation | 1 | 2020 | 2249 | 0.12 | Why? |
| Humans | 44 | 2021 | 930598 | 0.12 | Why? |
| Measles | 1 | 2019 | 608 | 0.11 | Why? |
| Orthomyxoviridae | 1 | 2020 | 1168 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.11 | Why? |
| Smell | 1 | 2020 | 1851 | 0.11 | Why? |
| Dyslipidemias | 1 | 2017 | 791 | 0.11 | Why? |
| Exanthema | 1 | 2020 | 1097 | 0.10 | Why? |
| Vaccination Coverage | 1 | 2019 | 1249 | 0.10 | Why? |
| Child | 5 | 2021 | 70012 | 0.10 | Why? |
| Cardiovascular Diseases | 3 | 2021 | 11497 | 0.10 | Why? |
| Pneumonia, Viral | 9 | 2020 | 243684 | 0.10 | Why? |
| Male | 21 | 2021 | 367725 | 0.10 | Why? |
| Pneumocystis carinii | 1 | 2010 | 205 | 0.09 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.09 | Why? |
| Diet | 1 | 2021 | 2052 | 0.09 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 1510 | 0.09 | Why? |
| Parkinson Disease | 1 | 2021 | 1414 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.09 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2010 | 260 | 0.09 | Why? |
| Neoplasms | 3 | 2021 | 17251 | 0.09 | Why? |
| Intestinal Pseudo-Obstruction | 1 | 2006 | 11 | 0.08 | Why? |
| Glucose | 1 | 2010 | 573 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.08 | Why? |
| Pneumonia, Pneumocystis | 1 | 2010 | 322 | 0.08 | Why? |
| Drug Discovery | 1 | 2020 | 3092 | 0.08 | Why? |
| Ritonavir | 1 | 2021 | 4212 | 0.08 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.08 | Why? |
| Adult | 11 | 2021 | 244371 | 0.07 | Why? |
| Immunity, Innate | 2 | 2020 | 6570 | 0.07 | Why? |
| Monocytes | 1 | 2017 | 2978 | 0.07 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.07 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.06 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.06 | Why? |
| Tuberculosis | 1 | 2019 | 2895 | 0.06 | Why? |
| Female | 15 | 2021 | 380317 | 0.06 | Why? |
| CD4 Lymphocyte Count | 2 | 2019 | 1517 | 0.06 | Why? |
| Cross Infection | 3 | 2019 | 8675 | 0.06 | Why? |
| Receptors, KIR2DL1 | 1 | 2021 | 23 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.06 | Why? |
| Insulin | 1 | 2010 | 1316 | 0.06 | Why? |
| Red Meat | 1 | 2021 | 39 | 0.06 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.06 | Why? |
| Carbonated Beverages | 1 | 2021 | 45 | 0.06 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.05 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2019 | 3633 | 0.05 | Why? |
| HIV-1 | 3 | 2019 | 3365 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2019 | 6331 | 0.05 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.05 | Why? |
| Receptors, KIR | 1 | 2021 | 167 | 0.05 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.05 | Why? |
| Mass Screening | 1 | 2019 | 8005 | 0.05 | Why? |
| Hospitals | 1 | 2019 | 11793 | 0.05 | Why? |
| Boutonneuse Fever | 1 | 2018 | 21 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2017 | 4741 | 0.05 | Why? |
| Tuberculin Test | 1 | 2019 | 141 | 0.05 | Why? |
| HIV Fusion Inhibitors | 1 | 2019 | 80 | 0.05 | Why? |
| Growth Hormone-Releasing Hormone | 1 | 2017 | 17 | 0.05 | Why? |
| Internship and Residency | 1 | 2019 | 4987 | 0.04 | Why? |
| Poly I-C | 1 | 2018 | 176 | 0.04 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.04 | Why? |
| Aged | 8 | 2021 | 215776 | 0.04 | Why? |
| Rehabilitation Centers | 1 | 2021 | 252 | 0.04 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.04 | Why? |
| Gram-Positive Bacteria | 1 | 2019 | 230 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 8811 | 0.04 | Why? |
| Candida albicans | 1 | 2019 | 217 | 0.04 | Why? |
| Blood Gas Analysis | 1 | 2021 | 893 | 0.04 | Why? |
| Attention | 1 | 2020 | 335 | 0.04 | Why? |
| Italy | 5 | 2021 | 38444 | 0.04 | Why? |
| Interferon-gamma Release Tests | 1 | 2019 | 253 | 0.04 | Why? |
| RNA, Double-Stranded | 1 | 2018 | 226 | 0.04 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.04 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.04 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 497 | 0.04 | Why? |
| RNA Virus Infections | 1 | 2018 | 231 | 0.04 | Why? |
| Pandemics | 9 | 2020 | 389249 | 0.04 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 581 | 0.04 | Why? |
| Risk | 2 | 2018 | 5288 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2019 | 9044 | 0.04 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2019 | 403 | 0.04 | Why? |
| Norovirus | 1 | 2019 | 294 | 0.04 | Why? |
| Body Weight | 1 | 2021 | 1074 | 0.04 | Why? |
| Hippocampus | 1 | 2017 | 237 | 0.03 | Why? |
| Gram-Negative Bacteria | 1 | 2019 | 473 | 0.03 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2006 | 1645 | 0.03 | Why? |
| Complement Activation | 1 | 2020 | 949 | 0.03 | Why? |
| Seroepidemiologic Studies | 2 | 2019 | 10017 | 0.03 | Why? |
| HIV | 1 | 2020 | 1116 | 0.03 | Why? |
| Cholesterol | 1 | 2017 | 660 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Sputum | 1 | 2020 | 1720 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2021 | 2742 | 0.03 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.03 | Why? |
| Databases, Genetic | 1 | 2017 | 1127 | 0.03 | Why? |
| Lipids | 1 | 2017 | 1079 | 0.03 | Why? |
| Interferon-gamma | 1 | 2020 | 2711 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Alcohol Drinking | 1 | 2021 | 1663 | 0.02 | Why? |
| Animals | 4 | 2020 | 78931 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| Skin | 1 | 2020 | 2096 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2021 | 2844 | 0.02 | Why? |
| Environmental Exposure | 1 | 2018 | 1558 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2019 | 48226 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.02 | Why? |
| Seasons | 1 | 2020 | 4071 | 0.02 | Why? |
| Data Collection | 1 | 2017 | 1769 | 0.02 | Why? |
| Macaca mulatta | 1 | 2017 | 3716 | 0.02 | Why? |
| Health Personnel | 1 | 2017 | 29646 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2018 | 2585 | 0.02 | Why? |
| Hospitals, University | 1 | 2019 | 4173 | 0.02 | Why? |
| Feces | 1 | 2020 | 4235 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2020 | 43792 | 0.02 | Why? |
| Immunization Programs | 1 | 2019 | 2006 | 0.02 | Why? |
| Pyrazines | 1 | 2017 | 1783 | 0.02 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2021 | 4027 | 0.02 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2017 | 1671 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Ultrasonography | 1 | 2021 | 4409 | 0.02 | Why? |
| Treatment Outcome | 1 | 2010 | 51732 | 0.02 | Why? |
| Occupational Diseases | 1 | 2019 | 2787 | 0.02 | Why? |
| Nursing Homes | 1 | 2021 | 4155 | 0.02 | Why? |
| Medical Oncology | 1 | 2020 | 3826 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2020 | 5164 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.01 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.01 | Why? |
| Virus Internalization | 1 | 2019 | 7921 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Incidence | 1 | 2019 | 25622 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2019 | 21571 | 0.01 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.01 | Why? |
| Immunity | 1 | 2002 | 2651 | 0.01 | Why? |
| RNA, Viral | 1 | 2018 | 32276 | 0.01 | Why? |
| Infant | 1 | 2006 | 30274 | 0.00 | Why? |